ArticleOncoimmunology2016

Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.

Xinmiao Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.